{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:26:21Z","timestamp":1791897981972,"version":"4.3.4"},"reference-count":164,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2002,4,22]],"date-time":"2002-04-22T00:00:00Z","timestamp":1019433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2002,4,22]],"date-time":"2002-04-22T00:00:00Z","timestamp":1019433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002068","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:33:39Z","timestamp":1069367619000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Bisphosphonates for the relief of pain secondary to bone metastases"],"prefix":"10.1002","volume":"2017","author":[{"given":"Rebecca KS","family":"Wong","sequence":"first","affiliation":[{"name":"The Princess Margaret Hospital; Department of Radiation Oncology; 5th Floor, 610 University Avenue Toronto ON Canada M5G 2M9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Wiffen","sequence":"additional","affiliation":[{"name":"University of Oxford; Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics); Pain Research Unit Churchill Hospital Oxford Oxfordshire UK OX3 7LE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,4,22]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF02906133","article-title":"The effect of two different doses of oral clodronate on pain in patients with bone metastases","volume":"16","author":"Arican","year":"1999","journal-title":"Medical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD002068-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002068-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group","volume":"101","author":"Brincker","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD002068-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s005200050148","article-title":"Different doses of pamidronate in patients with painful osteolytic bone metastases","volume":"6","author":"Cascinu","year":"1998","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0959-8049(97)10155-1","article-title":"A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer","volume":"34","author":"Coleman","year":"1998","journal-title":"European Journal of Cancer"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD002068-BIB0007|cit7","first-page":"S41","article-title":"Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial","volume":"5","author":"Conte","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0008|cit8","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Groupe d'Etudes et de Recherches sur le Myelome (GERM)","volume":"2","author":"Daragon","year":"1993","journal-title":"European Journal of Medicine"},{"key":"10.1002\/14651858.CD002068-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0221-8747(82)90013-3","article-title":"Long term effects of dichloromethylene diphosphonate on skeletal lesions in multiple myeloma","volume":"4","author":"Delmas","year":"1982","journal-title":"Metab Bone Dis & Rel Res"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer","volume":"24","author":"Elomaa","year":"1992","journal-title":"International Urology and Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0885-3924(92)90101-M","article-title":"A double-blind, crossover trial of intravenous clodronate in metastatic bone pain","volume":"7","author":"Ernst","year":"1992","journal-title":"Journal of Pain and Symptom Management"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"Journal of Pain and Symptom Management"},{"issue":"11","key":"10.1002\/14651858.CD002068-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q","article-title":"Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study","volume":"74","author":"Glover","year":"1994","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0014|cit14","first-page":"439","article-title":"Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie","volume":"18","author":"Heim","year":"1995","journal-title":"Onkologie"},{"issue":"24","key":"10.1002\/14651858.CD002068-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD002068-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3109\/02841869609083974","article-title":"Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study","volume":"35","author":"Hultborn","year":"1996","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s005200050218","article-title":"Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial","volume":"7","author":"Koeberle","year":"1999","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1002\/14651858.CD002068-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain - a double blind placebo-controlled study in patients with prostate cancer","volume":"76","author":"Kylmala","year":"1997","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002068-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000226904","article-title":"Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton","volume":"48","author":"Martoni","year":"1991","journal-title":"Oncology"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0021|cit21","first-page":"725","article-title":"Randomized trial of two intravenous schedules of bonephos (clodronate) in patients with painful bone metastases","volume":"44","author":"Moiseyenko","year":"1998","journal-title":"Voprosy Onkologii (Matters of Oncology)"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.1995.13.4.929","article-title":"Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases","volume":"13","author":"O'Rourke","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0023|cit23","first-page":"213","article-title":"A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy","volume":"17","author":"Piga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1002\/14651858.CD002068-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1200\/JCO.1995.13.9.2427","article-title":"Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study","volume":"13","author":"Robertson","year":"1995","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(83)90958-0","article-title":"Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton","volume":"74","author":"Siris","year":"1983","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"141","author":"Smith","year":"1989","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD002068-BIB0027|cit27","first-page":"4717","article-title":"The analgesic efficacy of clodronate compared with placebo in patients with painful bony metastases from prostatic cancer","volume":"17","author":"Strang","year":"1997","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","article-title":"Palliative pamidronate treatment in patients with bone metastases from breast cancer","volume":"11","author":"Holten-Verzantvoort","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD002068-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1008238422151","article-title":"Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease","volume":"8","author":"Vinholes","year":"1997","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0609.1998.tb01073.x","article-title":"Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma","volume":"61","author":"Abildgaard","year":"1998","journal-title":"European Journal of Haematology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD002068-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0959-8049(97)00149-4","article-title":"Pain control in patients with cancer","volume":"33","author":"Ahmedzai","year":"1997","journal-title":"European Journal Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0033|cit33","unstructured":"Berenson J Lichtenstein A Porter L Bordoni R George S Lipton A Pamidronate disodium reduced the occurence of skeletal-related events (SRE) in advanced multiple myeloma (MM) (Abstract) Blood 1994"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD002068-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1661::AID-CNCR16>3.0.CO;2-Y","article-title":"Bisphosphonates in multiple myeloma.","volume":"80","author":"Berenson","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0036|cit36","first-page":"195","article-title":"The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma","volume":"9","author":"Berenson","year":"1998","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"10.1002\/14651858.CD002068-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/02841869609083977","article-title":"Bisphosphonate therapy in metastatic breast cancer","volume":"35 Suppl 5","author":"Blomqvist","year":"1996","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.1998.16.3.1218","article-title":"Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers. An evidence based review","volume":"16","author":"Bloomfield","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF00326636","article-title":"Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research","volume":"1","author":"Body","year":"1993","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(96)90020-1","article-title":"Use of bisphosphonates in cancer patients","volume":"22","author":"Body","year":"1996","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1002\/14651858.CD002068-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology. International Bone and Cancer Study Group","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1002\/14651858.CD002068-BIB0042|cit42","first-page":"479","article-title":"Dichloromethylene diphosphonate in the treatment of lytic bone metastases","volume":"13","author":"Chantraine","year":"1984","journal-title":"Presse Medicale"},{"key":"10.1002\/14651858.CD002068-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI109780","article-title":"Effects of disodium dichoromethylene diphosphonate on hypercalcemia produced by bone metastases","volume":"65","author":"Chapuy","year":"1980","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD002068-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01697625","article-title":"Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications","volume":"66","author":"Clemens-MR","year":"1993","journal-title":"Ann-Hematol"},{"key":"10.1002\/14651858.CD002068-BIB0045|cit45","first-page":"24","article-title":"Pamidronate for the treatment of metastatic bone disease (Meeting abstract)","volume":"20","author":"Coleman","year":"1994","journal-title":"Cancer Conference 12th Asia Pacific"},{"key":"10.1002\/14651858.CD002068-BIB0046|cit46","unstructured":"Coleman RE Vinholes J Abbey ME Purohit OP Double-blind randomized trial of pamidronate (AREDIA) for the palliative treatment of metastatic, bone disease (Meeting abstract) Proc Annu Meet Soc Clin Oncol 1996 A1706"},{"key":"10.1002\/14651858.CD002068-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.0.CO;2-V","article-title":"High dose pamidronate - clinical and biochemical effects in metastatic bone disease","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"5","key":"10.1002\/14651858.CD002068-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/030089169307900511","article-title":"Disodium pamidronate in the treatment of bone metastases from breast cancer","volume":"79","author":"Colleoni","year":"1993","journal-title":"Tumori"},{"issue":"9","key":"10.1002\/14651858.CD002068-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group","volume":"14","author":"Conte","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0050|cit50","first-page":"71","article-title":"Disodium pamidronate (APD) in the treatment of bone metastases","volume":"6","author":"Costa","year":"1993","journal-title":"Acta Med Port"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00002512-199812020-00007","article-title":"Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone","volume":"12","author":"Coukell","year":"1998","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.1995.tb07715.x","article-title":"Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer","volume":"76","author":"Cresswell","year":"1995","journal-title":"British Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD002068-BIB0053|cit53","first-page":"266","article-title":"A randomized controlled trial of intravenous clodronate","volume":"15","author":"Crosby","year":"1998","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD002068-BIB0054|cit54","first-page":"1471","article-title":"Dichloromethylene diphosphonate (CL2MDP) treatment of hypercalcemia produced from bone metastases (Authors' translation)","volume":"11","author":"Delmas","year":"1982","journal-title":"Nouvelle Presse Medicale"},{"key":"10.1002\/14651858.CD002068-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/8756-3282(91)90064-P","article-title":"The use of clodronate in multiple myeloma","volume":"12 Suppl 1","author":"Delmas","year":"1991","journal-title":"Bone"},{"issue":"24","key":"10.1002\/14651858.CD002068-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJM199612123352409","article-title":"Bisphosphonates in the treatment of bone diseases","volume":"335","author":"Delmas","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD002068-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/jnci\/90.18.1329","article-title":"Bisphosphonates: lingering questions about their use","volume":"90","author":"Derrane","year":"1998","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1002\/14651858.CD002068-BIB0058|cit58","unstructured":"Diel IJ Solomayer EF Goerner R Gollan C Wallwiener D Bastea G Adjuvant treatment of breast cancer patients with bisphosphonate clodronate reduces incidence and number of bone and non-bone metastases (meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1997 A461"},{"key":"10.1002\/14651858.CD002068-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD002068-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/ajhp\/53.16.1917","article-title":"Bisphosphonates for controlling pain from metastatic bone disease","volume":"53","author":"Diener","year":"1996","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/bjc.1990.25","article-title":"Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate","volume":"61","author":"Dodwell","year":"1990","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003495-199957010-00011","article-title":"Ibandronate","volume":"57","author":"Dooley M. Balfour","year":"1999","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1017\/S0266462399015202","article-title":"Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?","volume":"15","author":"Dranitsaris","year":"1999","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s005200050260","article-title":"Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer","volume":"7","author":"Dranitsaris","year":"1999","journal-title":"Support Care Cancer"},{"issue":"8317","key":"10.1002\/14651858.CD002068-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long term controlled trial with diphosphonate in patients with osteolytic bone metastases.","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002068-BIB0066|cit66","first-page":"S53","article-title":"Treatment of skeletal disease in breast cancer: a controlled clodronate trial","volume":"8 Suppl 1","author":"Elomaa","year":"1987","journal-title":"Bone"},{"key":"10.1002\/14651858.CD002068-BIB0067|cit67","first-page":"111","article-title":"Clodronate for osteolytic metastases due to breast cancer","volume":"42","author":"Elomaa","year":"1988","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1002\/14651858.CD002068-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1515\/CCLM.1998.154","article-title":"Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease","volume":"36","author":"Engler","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"10.1002\/14651858.CD002068-BIB0069|cit69","unstructured":"Ernst DS Brasher P Hagen N Paterson A MacDonald RN Bruera E Randomized, controlled trial of IV clodronate in patients with painful bone metastases (Meeting abstract) Pro Annu Meetg Am Soc Clin Oncol 1993 A1563"},{"key":"10.1002\/14651858.CD002068-BIB0070|cit70","unstructured":"Ernst DS Brasher P Hagen N Paterson A MacDonald RN Bruera E Controlled trial of intravenous clodronate in patients with metastastic bone disease and pain (Meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1994 A1478"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00003495-199141020-00009","article-title":"Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease","volume":"41","author":"Fitton","year":"1991","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002068-BIB0072|cit72","unstructured":"Fontana A Herrmann Z Menssen HD Sakalova A Boewer C Facon T Effects if intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma Blood 1998"},{"issue":"9","key":"10.1002\/14651858.CD002068-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0011-393X(95)85087-2","article-title":"Oral bisphosphonates in the treatment of osteoporosis: A review","volume":"56","author":"Francis","year":"1995","journal-title":"Current Therapeutic Research Clinical and Experimental"},{"key":"10.1002\/14651858.CD002068-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"10.1002\/14651858.CD002068-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1001\/archinte.1994.00420170079008","article-title":"Treatment of cancer-associated hypercalcemia: Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone","volume":"154","author":"Gucalp","year":"1994","journal-title":"Archives of Internal Medicine"},{"issue":"8861","key":"10.1002\/14651858.CD002068-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/0140-6736(93)90756-7","article-title":"Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia","volume":"341","author":"Gurney","year":"1993","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01682343","article-title":"The role of bisphosphonates in the treatment of bone metastases--the U.S. experience","volume":"4","author":"Harvey","year":"1996","journal-title":"Support Care Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN Porter L Blayney D Theriault RL Lipton A Gluck S Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT) by monthly pamidronate sodium (PAM) (AREDIA) infusion (Meeting abstract) Pro Annu Meet Am Soc Clin Oncol 1996 A99","DOI":"10.1016\/0959-8049(96)84243-2"},{"key":"10.1002\/14651858.CD002068-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN Porter L Blayney D Theriault RL Lipton A Gluck S Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (AREDIA) infusion (meeting abstract) Pro Annu Meet Am Soc Clin Oncol 1997 A530","DOI":"10.1016\/0959-8049(96)84243-2"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0081|cit81","unstructured":"Hulin MT Beuzeboc P Mauriac L Clavel M Barbet N Frenay M Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer. Effect on induced hyperosteolysis - preliminary results (Meeting abstract) Annals of Oncology 1994 8"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0082|cit82","first-page":"183","article-title":"Pamidronate disodium in the treatment of osteolytic lesions and bone pain in patients with bone metastases associated with breast cancer","volume":"9","author":"Iddon","year":"1998","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"10.1002\/14651858.CD002068-BIB0083|cit83","unstructured":"Iveson TJ Powle TJ Tidy A Ashley S Kanis J Paterson A Clodronate decreases the incidence of bone metastases in patients with advanced or metastastic breast cancer but no clinical evidence of bone metastases (Meeting abstract) British Journal of Cancer 1994 24"},{"issue":"25","key":"10.1002\/14651858.CD002068-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198306233082503","article-title":"Use of dichloromethylene diphosphate in metastatic bone disease","volume":"308","author":"Jung","year":"1983","journal-title":"New England Journal of Medicine"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD002068-BIB0085|cit85","first-page":"1691","article-title":"Clodronate","volume":"80","author":"Kanis","year":"1991","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"key":"10.1002\/14651858.CD002068-BIB0087|cit87","unstructured":"Koberle D Thurlimann B Engler H Bacchus L Senn HJ Riesen W Double blind intravenous pamidronate (APD) 60mg versus 90mg in patients with malignant osteolytic bone disease and pain (Meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1997 A182"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0959-8049(05)80417-4","article-title":"Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group","volume":"29","author":"Kylmala","year":"1993","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2141.1994.tb06730.x","article-title":"Subgroup and cost-benefit analysis of the Finnish Multicenter trial of clodronate in multiple myeloma","volume":"87","author":"Laakso","year":"1994","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD002068-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/ajhp\/53.16.1907","article-title":"Pain management for bone metastases","volume":"53","author":"LaCivita","year":"1996","journal-title":"Am J Health Syst Pharm"},{"key":"10.1002\/14651858.CD002068-BIB0092|cit92","unstructured":"Lipton A Glover D Harvey H Grabelsky S Givant E Lipton N Disodium pamidronate (APD) - a dose seeking study in patients with breast and prostate cancer: preliminary report (Meeting abstract) Osteoclast inhibition in the management of malignant related bone disorders 1994"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD002068-BIB0093|cit93","first-page":"S31","article-title":"Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer","volume":"5","author":"Lipton","year":"1994","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0094|cit94","unstructured":"Lipton A Theriault R Leff R Gluck S Stewart J Costello S Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90mg pamidronate (Aredia) infusions (Meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1997 A531"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002068-BIB0095|cit95","first-page":"S1","article-title":"Aredia: the once monthly infusion for the treatment of bone metastases","volume":"10","author":"Lipton","year":"1998","journal-title":"Current Opinion in Oncology"},{"issue":"13","key":"10.1002\/14651858.CD002068-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0959-8049(98)00277-9","article-title":"Markers of bone resorption in patients treated with pamidronate","volume":"34","author":"Lipton","year":"1998","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1002\/14651858.CD002068-BIB0098|cit98","first-page":"732","article-title":"Bisphosphonates and bone metastases","volume":"86","author":"Lortholary","year":"1999","journal-title":"Bulletin Cancer"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0099|cit99","first-page":"310","article-title":"Treatment of metastatic bone pain with Aredia (pamidronate)","volume":"20","author":"Maolin","year":"1998","journal-title":"Chinese Journal of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD002068-BIB0100|cit100","first-page":"1877","article-title":"Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo","volume":"32","author":"Maxon","year":"1991","journal-title":"Journal of Nuclear Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002068-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"1-2","key":"10.1002\/14651858.CD002068-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: Pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hon.2900080104","article-title":"Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy","volume":"8","author":"Merlini","year":"1990","journal-title":"Hematological Oncology"},{"issue":"5","key":"10.1002\/14651858.CD002068-BIB0104|cit104","first-page":"81-4, 88-9, 93-","article-title":"Bisphosphonates as cancer drugs","volume":"35","author":"Mundy","year":"1999","journal-title":"Hospital Practice (Office Edition)"},{"issue":"5-6","key":"10.1002\/14651858.CD002068-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/10428199809057605","article-title":"The role of bisphosphonates for the treatment of bone disease in multiple myeloma","volume":"31","author":"Musto","year":"1998","journal-title":"Leukemia & Lymphoma"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002068-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/8756-3282(91)90058-Q","article-title":"Clinical consequences of osteolytic bone metastases","volume":"12","author":"Namer","year":"1991","journal-title":"Bone"},{"key":"10.1002\/14651858.CD002068-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/8756-3282(91)90063-O","article-title":"Treatment of skeletal disease in breast cancer with clodronate","volume":"Suppl 1","author":"Paterson","year":"1991","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"10 Suppl 6","key":"10.1002\/14651858.CD002068-BIB0109|cit109","first-page":"50","article-title":"Double blind trial of oral clodronate in breast cancer patients with bone metastases","volume":"80","author":"Paterson","year":"1993","journal-title":"Bulletin du Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0110|cit110","unstructured":"Paterson AG Goss G Murphy K Brennan JM Quality of life measurement using the FLI-C in breast cancer patients receiving single agent mitoxantrone (Meeting Abstract) International Association for Breast Cancer Research 1994 25 8"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s005200050060","article-title":"Should bisphosphonates be standard therapy for bone pain?","volume":"5","author":"Paterson","year":"1997","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1043-2760(98)00097-6","article-title":"The emerging role of bisphosphonates in the prevention of bone metastases","volume":"10","author":"Paterson","year":"1999","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD002068-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0959-8049(96)00228-6","article-title":"Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use of monitoring of intravenous clodronate therapy - a pilot study of the German Myeloma Treatment Group (GMTG)","volume":"32A","author":"Peest","year":"1996","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S8756-3282(97)00289-5","article-title":"Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton","volume":"22","author":"Pelger","year":"1998","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2165\/00003495-199447060-00007","article-title":"Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease","volume":"47","author":"Plosker","year":"1994","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD002068-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Powles T Clodronate: the potential for the future Bone 1991 S43 44","DOI":"10.1016\/8756-3282(91)90067-S"},{"issue":"9","key":"10.1002\/14651858.CD002068-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bjc.1994.344","article-title":"High-dose intravenous pamidronate for metastatic bone pain","volume":"70","author":"Purohit","year":"1994","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0119|cit119","first-page":"174","article-title":"Improvement of palliation in patients with osteolytic bone disease and unsatisfactory pain control after pretreatment with disodium pamidronate: An intra-patient dose escalation study","volume":"16","author":"Radziwill","year":"1993","journal-title":"Onkologie"},{"issue":"5","key":"10.1002\/14651858.CD002068-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0121|cit121","first-page":"833","article-title":"Prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma","volume":"5","author":"Riccardi","year":"1994","journal-title":"International Journal of Oncology"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/030089169808400403","article-title":"Role of pamidronate disodium in the treatment of metastatic bone disease","volume":"84","author":"Ripamonti","year":"1998","journal-title":"Tumori"},{"key":"10.1002\/14651858.CD002068-BIB0123|cit123","unstructured":"Rose C Ford J Becher R Possinger K Coleman R Rubens RD Pamidronate disodium (Aredia) dose effect and tolerability evaluation in breast cancer patients with bone metastases (Meeting abstract) Annals of Oncology 1992 5"},{"key":"10.1002\/14651858.CD002068-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0959-8049(92)90143-P","article-title":"Intravenous clodronate for the treatment of hypercalcemia in breast cancer patients with bone metastases: a prospective randomized placebo- controlled multicenter study","volume":"28A","author":"Rotstein","year":"1992","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0125|cit125","first-page":"99","article-title":"Use of intravenous etidronate disodium in the treatment of hypercalcemia","volume-title":"Bone resorption, metastasis and diphosphonates. Monographs of athe Mario Negri Institute for Pharmacological Research","author":"Ryzen","year":"1985"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0126|cit126","first-page":"445","article-title":"A clinical trial of Bonin in bone metastases of lung cancer","volume":"26","author":"Shucai","year":"1999","journal-title":"Chinese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198002073020602","article-title":"Effect of dicholoromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma","volume":"302","author":"Siris","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002068-BIB0128|cit128","doi-asserted-by":"crossref","unstructured":"Strang P Analgesic effect of bisphosphonates on bone pain in breast cancer patients. A review article Acta Oncologica 1996 50 4","DOI":"10.3109\/02841869609083968"},{"issue":"6","key":"10.1002\/14651858.CD002068-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/0959-8049(94)90287-9","article-title":"The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study","volume":"30","author":"Taube","year":"1994","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0130|cit130","first-page":"8-12 (discussio","article-title":"Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients","volume":"87","author":"Theriault","year":"1996","journal-title":"Br J Clin Pract Suppl"},{"key":"10.1002\/14651858.CD002068-BIB0131|cit131","doi-asserted-by":"crossref","unstructured":"Theriault R Lipton A Leff R Gluck S Stewart J Costello S Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (Aredia) infusion (Meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1996 A152","DOI":"10.1016\/0959-8049(96)84244-4"},{"key":"10.1002\/14651858.CD002068-BIB0132|cit132","unstructured":"Thurlimann B Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? Ann Oncol 1994 S45 7"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00355241","article-title":"Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study","volume":"2","author":"Thurlimann","year":"1994","journal-title":"Support Care Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0134|cit134","unstructured":"Tubiana-Hulin M Beuzeboc P Mauriac L Barbet N Frenay M Monnier A Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer: effects on induced hyperosteolysis (Meeting abstract) Proc Annu Meet Am Soc Clin Oncol 1995 A1718"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD002068-BIB0135|cit135","first-page":"37","article-title":"Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial","volume":"5","author":"Tyrrell","year":"1994","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD002068-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/0959-8049(95)00469-6","article-title":"Pamidronate infusions as single-agent therapy for bone metastases: A phase II trial in patients with breast cancer","volume":"31","author":"Tyrrell","year":"1995","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD002068-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0277-5379(91)90212-V","article-title":"The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer","volume":"27","author":"Holten Verzantvoort","year":"1991","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0138|cit138","article-title":"Long-term bisphosphonate treatment of bone metastases in breast cancer patients? (Meeting abstract)","author":"Holten-Verzantvoort","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0959-8049(95)00564-1","article-title":"Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?","volume":"32A","author":"Holten-Verzantvoort","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/bjc.1996.210","article-title":"Metabolic effects of pamidronate in patients with metastatic bone disease","volume":"73","author":"Vinholes","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0141|cit141","unstructured":"Vinholes J Purohit OP Eastell R Coleman RE Evaluation of new bone resorption markers in a randomised trial of pamidronate for metastatic bone pain (Abstract) Br J Cancer 1996 16"},{"issue":"1","key":"10.1002\/14651858.CD002068-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.1997.15.1.131","article-title":"Evaluation of new bone resoption markers in a randomised comparison of pamidronate or clodronate for hypercalcaemia of malignancy","volume":"15","author":"VinholesJ","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD002068-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1464-410X.1993.tb16269.x","article-title":"Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate","volume":"72","author":"Vorreuther","year":"1993","journal-title":"Br J Urol"},{"issue":"9","key":"10.1002\/14651858.CD002068-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1023\/A:1008274608267","article-title":"Subcutaneous clodronate: a study evaluating efficacy in hypercalcaemia of malignancy and local toxicity","volume":"8","author":"Walker","year":"1997","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0145|cit145","first-page":"32","article-title":"Zoledronic acide reduces skeletal related events in patients with oseolytic metastases: a double-blind, randomized dose response study","volume":"64","author":"Berenson","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1002\/14651858.CD002068-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0147|cit147","first-page":"379","article-title":"The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma","volume":"31","author":"Kraj","year":"2000","journal-title":"Acta Haematologica Palonica"},{"key":"10.1002\/14651858.CD002068-BIB0148|cit148","first-page":"113","article-title":"Effect of pamidronate on skeletal morbidity in myelomatosis. Part I: The results of the 12 months of pamidronate therapy","volume":"57 (suppl)","author":"Kraj","year":"2000","journal-title":"Acta Poloniae Pharmaceutica"},{"key":"10.1002\/14651858.CD002068-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1002\/14651858.CD002068-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD002068-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1002\/14651858.CD002068-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(96)90020-1","article-title":"Use of bisphosphonates in cancer patients","volume":"22","author":"Body","year":"1996","journal-title":"Cancer Treatment Reviews"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0153|cit153","first-page":"144","article-title":"Use of bisphosphonates in patients with bone metastases from breast cancer","volume":"6","author":"Bloomfield","year":"1999","journal-title":"Current Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0154|cit154","first-page":"391","article-title":"Measurement of pain by subjective report","volume-title":"Issues in pain management. Advances in pain research and therapy","volume":"12","author":"Cleeland","year":"1989"},{"key":"10.1002\/14651858.CD002068-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Systematic reviews: identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002068-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD002068-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/026921601671919596","article-title":"Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK","volume":"15","author":"Johnson","year":"2001","journal-title":"Palliative Medicine"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD002068-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1668::AID-CNCR17>3.0.CO;2-Y","article-title":"Bisphosphonates and breast carcinoma","volume":"80","author":"Lipton","year":"1997","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD002068-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1191\/026921600701536372","article-title":"Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care","volume":"14","author":"Mannix","year":"2000","journal-title":"Palliative Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002068-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0936-6555(97)80070-2","article-title":"Radiotherapy for painful bone metastases: a systematic review","volume":"9","author":"McQuay","year":"1997","journal-title":"Clinical Oncology"},{"key":"10.1002\/14651858.CD002068-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/bmj.312.7033.742","article-title":"Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology","volume":"312","author":"Schulz","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002068-BIB0162|cit162","first-page":"343","article-title":"Differences and similarities between patient and physician perceptions of patient pain","volume":"20","author":"Sutherland","year":"1988","journal-title":"Family Medicine"},{"key":"10.1002\/14651858.CD002068-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0304-3959(89)90179-6","article-title":"Patients' and nurses' ratings of pain and anxiety during burn wound care","volume":"39","author":"Does","year":"1989","journal-title":"Pain"},{"key":"10.1002\/14651858.CD002068-BIB0164|cit164","first-page":"15","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment","volume":"48","author":"World Health Organization","year":"1979"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002068\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:43:39Z","timestamp":1684298619000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002068"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2002,4,22]]},"references-count":164,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002068","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718242838.793489810","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,22]]}}}